Skip to content
    SIGA
    Earnings call· Jun 2026(Q2 FY26)

    SIGA TECHNOLOGIES Q2 FY26 earnings call SIGA

    Aug 6, 2026 Source

    Executive summary

    SIGA Q2 FY26 — Strong Product Revenue and International Expansion

    SIGA Technologies reported strong Q2 FY26 product revenues driven by U.S. stockpile deliveries and international sales, demonstrating diversification. While the U.S. contract renewal process faces delays, the company is actively pursuing international expansion and advancing its pipeline, maintaining a robust financial position. The business model inherently experiences quarterly variability, emphasizing a longer-term view.

    Highlights

    5

    • Product-related revenues reached $38 million in Q2 FY26.

    • Successfully delivered $24 million of IV TPOX to the U.S. Strategic National Stockpile, fulfilling the final order under the 19C contract.

    • Achieved $13 million in oral TPOX sales to two international customers, diversifying revenue streams.

    • Maintained a strong balance sheet with approximately $118 million in cash and no debt as of June 30, 2026.

    • Entered into an exclusive license and distribution agreement with HCMA MENA FCE to expand TPOX's footprint across the MENA region.

    Concerns

    2

    • The U.S. RFP process for a new multi-year procurement contract has been slower than expected due to changes within HHS and open leadership positions.

    • The business model exhibits inherent quarter-to-quarter variability, with minimal product revenues recorded in Q1 FY26.

    Guidance & targets

    1
    CategoryTargetConfidence
    International TPOX delivery
    Delivery by March of next year
    medium materiality
    Medium

    Operational metrics

    6
    Product-related revenues
    $38 million
    Q2 FY26

    Product-related revenues for the second quarter.

    Product-related revenues
    $41 million
    YTD June 30, 2026

    Product-related revenues for the six months ended June 30, 2026.

    Research and development revenues
    $3 million
    Q2 FY26

    Research and development revenues for the three months ended June 30, 2026.

    Research and development revenues
    $6 million
    YTD June 30, 2026

    Research and development revenues for the six months ended June 30, 2026.

    Cash balance
    $118 million
    As of June 30, 2026

    Company's cash balance at the end of the quarter.

    Meridian Agreement Status
    Expired
    May 2026

    The Meridian Agreement officially expired in May, but SIGA has been managing international sales and distribution since 2024.

    Industry KPIs

    2
    MetricValueDetails
    Pipeline clinical milestonesPEP FDA submission targeted H1 2027; Pediatric Phase 1 results by year-end 2026
    Regulatory approvals filingsFDA submission targeted H1 2027 for TPOX PEP

    Deals & partnerships

    1
    HCMA MENA FCEExclusive license and distribution agreement for TPOX in the MENA region

    HCMA holds the right to register and commercialize TPOX across the Middle East and North Africa. SIGA and HCMA are developing a detailed plan to expand TPOX's presence in these markets where SIGA has been historically underrepresented. HCMA's regional presence and expertise are key to expanding access to TPOX in these markets. The agreement was recently entered into, and meetings are ongoing to develop a detailed plan for expansion. The quote is: "we recently entered into an exclusive license and distribution agreement with HCMA MENA FCE in connection with the MENA region. which includes countries in the Middle East and North Africa."

    Risks & headwinds

    3
    Slower pace of U.S. government contract renewal for TPOX.Ongoing

    slower than in the past

    Mitigation: Active engagement with U.S. government across multiple levels; confidence in TPOX's role due to ongoing funding for development programs and recent deliveries.

    Inherent quarter-to-quarter variability in business model.Ongoing

    minimal product revenues in Q1 FY26

    Mitigation: Results are best understood in the context of a longer horizon rather than any single period.

    Complexity of government procurement processes.Ongoing

    complex process

    Mitigation: Continued engagement with governments and key stakeholders as they assess preparedness strategies.

    What to watch in Q3 FY26

    3

    International TPOX contract and delivery

    Q1 FY27
    CurrentDiscussions progressing with an international customer
    TargetNew contract and order, delivery by March 2027

    Why it matters

    Signals continued international expansion and revenue diversification, potentially offsetting U.S. contract delays.

    discussions with an international customer have been progressing to the point that we're targeting a new contract as well well as an order against it and targeting hopefully💬 a delivery in that order by March of the next year.

    Q&A highlights

    3

    Why is the US RFP delayed, is a H2 award possible, and will it support 2027 deliveries?

    The delay is attributed to changes within HHS, new initiatives, evolving priorities, contract transition, and open leadership positions. Management believes TPOX's role in US preparedness is strong, but did not confirm H2 award or 2027 delivery timing for the US contract.

    “We believe the scale of change within HHS, including new initiatives, evolving priorities, transition of our contract from BARDA to S&S, and also key open leadership positions have been a meaningful contributor to the slower pace toward this new contract.”

    asked by Jyoti Prakash · answered by Unknown Speaker

    2 min read5 chapters

    Detailed Narrative

    01

    U.S. Government Engagement and Contract Status

    SIGA completed the final $24 million IV TPOX delivery under its 19C contract to the U.S. Strategic National Stockpile. The company is actively engaging with the U.S. government for a new multi-year procurement contract, though the process has been slower than anticipated due to changes within HHS and leadership vacancies. Management remains confident in TPOX's role in U.S. smallpox preparedness, citing ongoing funding for development programs.

    02

    International Market Expansion

    International sales contributed $13 million in Q2 FY26, including an order from the Asia Pacific region and a new European customer. SIGA recently entered an exclusive license and distribution agreement with HCMA MENA FCE to expand TPOX's footprint across the Middle East and North Africa, leveraging HCMA's regional expertise. The company is targeting a new international contract and delivery by March of next year.

    03

    Pipeline Advancement

    SIGA is progressing its post-exposure prophylaxis (PEP) and pediatric programs. For the PEP program, an FDA submission is targeted for the first half of 2027, following CDC's work on immunogenicity samples. Phase one study results for the pediatric program, which aims to provide a purpose-built liquid formulation for children, are expected by year-end 2026.

    04

    Financial Performance and Balance Sheet

    The company reported $38 million in product-related revenues for Q2 FY26, contributing to $41 million for the first six months of 2026. Research and development revenues were $3 million for the quarter. SIGA maintains a strong balance sheet with approximately $118 million in cash and no debt as of June 30, 2026, supporting financial and operational discipline.

    05

    Strategic Focus on Preparedness

    SIGA emphasizes the enduring need for governments to invest in medical countermeasure stockpiles against biological threats like smallpox. The company positions TPOX for rapid, large-scale deployment and believes its diversified sales across formulations and customers demonstrate its critical role in global preparedness strategies.

    AI-generated summary of the company’s earnings call. Not investment advice.